Chan K W, Mullen C A, Worth L L, Choroszy M, Koontz S, Tran H, Slopis J
Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Bone Marrow Transplant. 2002 Jun;29(12):963-5. doi: 10.1038/sj.bmt.1703593.
Seizure is a recognized complication of high-dose busulfan (BU) therapy and phenytoin (DPH) is widely used as prophylaxis. A number of adverse effects have been associated with DPH and it may also interfere with BU metabolism. We used lorazepam (median dose 0.022 mg/kg) i.v. or p.o. before each dose and for 24 h after the last dose of BU as seizure prophylaxis to 29 children undergoing hematopoietic stem cell transplantation. The regimen was well tolerated and drowsiness was the only significant side-effect. Twelve patients were able to receive the entire prophylaxis by mouth. No seizure developed during and within 48 h of BU. Concomitant pharmacokinetic studies showed no alternation of the absorption and clearance of BU during lorazepam administration. Lorazepam can be used as an alternative for seizure prophylaxis during high-dose BU treatment.
癫痫发作是高剂量白消安(BU)治疗公认的并发症,苯妥英(DPH)被广泛用作预防药物。DPH存在多种不良反应,并且它可能还会干扰BU的代谢。我们对29例接受造血干细胞移植的儿童,在每次服用BU前静脉注射或口服劳拉西泮(中位剂量0.022mg/kg),并在最后一剂BU后持续24小时用作癫痫预防。该方案耐受性良好,嗜睡是唯一显著的副作用。12例患者能够通过口服完成整个预防疗程。在服用BU期间及之后48小时内未发生癫痫发作。同时进行的药代动力学研究表明,在给予劳拉西泮期间,BU的吸收和清除没有改变。劳拉西泮可作为高剂量BU治疗期间癫痫预防的替代药物。